GWM
ANIP icon

Graybill Wealth Management’s ANI Pharmaceuticals ANIP Stock Holding History

Graybill Wealth Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-277
Closed -$18.5K – 84
2025
Q1 		$18.5K Buy
+277
New +$16.5K 0.01% 123

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Graybill Wealth Management's ANIP Position: Q2 2025 in Review

Graybill Wealth Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2025, closing a stake of 277 shares — an estimated $18.5K sold.

Graybill Wealth Management first reported a position in ANIP in Q1 2025 and held it in 1 quarter. The position peaked at $18.5K in Q1 2025. 232 funds tracked by Wall St. Rank hold ANIP as of Q2 2025.

  • Graybill Wealth Management reported no remaining ANI Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Graybill Wealth Management sold 277 ANI Pharmaceuticals shares in Q2 2025, an estimated $18.5K.
  • Graybill Wealth Management first reported a position in ANI Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Graybill Wealth Management's ANI Pharmaceuticals position peaked at $18.5K in Q1 2025.
  • 232 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2025.

Based on Graybill Wealth Management's 13F filing for Q2 2025, filed 31 Jul 2025.